
IdentifySensors Biologics Moves New Pathogen Testing Platform to Commercialization Stage

2021-05-21

Nanotechnology firm, IdentifySensors Biologics, in partnership with Purdue University, announced that it has completed development of an all-new diagnostic technology platform that detects numerous pathogens, including COVID-19, using electronic nanosensors. The company has moved the research and testing into its commercialization stage, where engineers are finalizing designs for large-scale, roll-to-roll manufacturing.

Replacing 50-year-old chemical diagnostics, such as PCR and antigen tests, with printed nanosensors is expected to significantly disrupt the \$50-billion diagnostics industry, not only for COVID-19 but for a wide range of diseases, said [IdentifySensors Biologics](#) CEO, Gregory Hummer, MD.

"We are excited to announce that we have proven this breakthrough concept and have moved into the large-scale manufacturing stage," Dr. Hummer said. "[Purdue University](#) has been a great partner helping with the development. We will continue working with the university's scientists on a series of sensors for additional pathogens on this platform."



Check4 by IdentifySensors Biologics has moved its newly proven nanosensor technology to the commercialization stage. The company intends to produce a pathogen-testing platform that rapidly and accurately detects a wide range of infections, including COVID-19, Influenza, Hepatitis C, Lyme and HIV.

The reusable reader sends results to a user's smartphone.

IdentifySensors Biologics has applied the new technology to a commercial device called Check4™, an over-the-counter reusable reader that integrates with a consumer's smartphone. Single-use test cartridges, which will be sold separately, slide into the reusable reader and send test results from a saliva sample wirelessly to a phone in minutes.

Unlike a chemical PCR test, the rapid Check4™ device requires no amplification, reagents or laboratory work. The test's accuracy often surpasses PCR tests, while each test cartridge is expected to cost less than \$25. Purdue University soon will begin developing new test cartridges for Influenza, Lyme, HIV and MRSA.

IdentifySensors Biologics has begun raising capital to fund its large-scale production of the platform. For details, visit the company's [investment page](#). The company plans to seek FDA approval this summer, while taking orders from organizations and governments that do not require FDA approval.

"This new platform technology takes pathogen testing down a completely different path than all the other diagnostic tests out there," said Richard Kuhn, director of Purdue University's Institute of Inflammation, Immunology and Infectious Disease.

Read the [original article](#) on PR Newswire.